Maina Theodosia, Nock Berthold, Mather Stephen
Institute of Radioisotopes--Radiodiagnostic Products, NCSR Demokritos, Athens, Greece.
Cancer Imaging. 2006 Nov 8;6(1):153-7. doi: 10.1102/1470-7330.2006.0025.
The fact that a number of common human tumours, including those of breast and prostate, express increased levels of the gastrin-releasing peptide receptor (GRP-R) means that this receptor is a potential target for peptide receptor mediated scintigraphy and targeted radionuclide therapy. Although clinical application is yet in its infancy, there is a considerable literature on preclinical studies aimed at developing suitable radioligands for potential clinical application. This brief review provides an overview of this research and also describes some of the limited clinical studies that have been published.
包括乳腺癌和前列腺癌在内的许多常见人类肿瘤表达胃泌素释放肽受体(GRP-R)的水平升高,这意味着该受体是肽受体介导的闪烁扫描和靶向放射性核素治疗的潜在靶点。尽管临床应用尚处于起步阶段,但已有大量关于临床前研究的文献,旨在开发适用于潜在临床应用的放射性配体。本简要综述概述了这项研究,并描述了已发表的一些有限的临床研究。